MAPT and Alzheimer disease: It is noteworthy that, according to current AD diagnostic criteria, MRI is considered a progression biomarker, rather than a diagnostic one, because of the suboptimal diagnostic performance, mainly in the view of early AD diagnosis, in terms of sensitivity and specificity, compared to the CSF and tau/amyloid PET biomarkers.